Dupixent (dupilumab) — Medica

Initial criteria

• age ≥ 6 months
• Atopic dermatitis involving ≥ 10% body surface area OR moderate to severe hand and/or foot atopic dermatitis and age ≥ 12 years
• Tried at least one medium-, medium-high-, high-, or super-high-potency prescription topical corticosteroid applied daily for ≥ 28 consecutive days with inadequate efficacy per prescriber
• Prescribed by or in consultation with an allergist, immunologist, or dermatologist

Reauthorization criteria

• Patient has already received ≥ 4 months of Dupixent therapy
• Patient has responded to therapy as determined by prescriber (e.g., improvement in erythema, induration/papulation/edema, excoriations, lichenification, pruritus, reduced need for other therapy, or reduced affected body surface area)

Approval duration

initial 4 months, reauthorization 1 year